Citations

Showing 10 of 108135 citations.

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study
Pal, Sumanta K. , McGregor, Bradley A. , Suárez, Cristina, Tsao, Che-Kai, Kelly, William, Vaishampayan, Ulka N. , Pagliaro, Lance, Maughan, Benjamin L. , Loriot, Yohann , Castellano, Daniel, Srinivas, Sandy, McKay, Rana R. , Dreicer, Robert, Dubey, Sarita, Werneke, Scott, Panneerselvam, Ashok, Curran, Dominic, Scheffold, Christian, Choueiri, Toni K. , McGregor, Bradley , Vaishampayan, Ulka , Hutson, Thomas , Choueiri, Toni K , Agarwal, Archana M , Loriot, Yohann , Pal, Sumanta K , Suárez, Cristina, Tsao, Che-Kai, Kelly, William, Pagliaro, Lance, Maughan, Benjamin L. , Castellano, Daniel, Srinivas, Sandy, McKay, Rana R , Dreicer, Robert, Dubey, Sarita, Werneke, Scott, Panneerselvam, Ashok, Curran, Dominic, Scheffold, Christian

Mayo Clinic

Journal of Clinical Oncology | September 7, 2021 | Volume: 39 | Issue: 33 | Pages: 3725-3736

10.1200/jco.21.00939 | PMID 34491815 Get It

PURPOSE COSMIC-021 is evaluating cabozantinib plus atezolizumab in patients with solid tumors. We report results from patients with advanced clear cell (cc) and non–clear cell (ncc) renal cell carcinoma (RCC). METHODS This phase Ib study ( NCT03170960 ) enrolled patients age ≥ 18 years with advanced RCC. A dose-escalation stage was followed by expansion cohorts. For cohort expansion, prior systemic therapy was not permitted for ccRCC but allowed for nccRCC. Patients received oral cabozantinib 40 mg once a day (ccRCC and nccRCC) or 60 mg once a day (ccRCC only) plus atezolizumab (1,200 mg intravenously, once every 3 weeks). The primary end point was investigator-assessed objective response rate (ORR) per RECIST v1.1; the secondary end point was safety. RESULTS A total of 102 patients were enrolled. Median follow-up was 25.8, 15.3, and 13.3 months for the 40-mg ccRCC, 60-mg ccRCC, and nccRCC groups, respectively. ORR was 53% (80% CI, 41 to 65) in the 40-mg ccRCC group (n = 34) and 58% (80% CI, 46 to 70) in the 60-mg ccRCC group (n = 36), 3% and 11%, respectively, with complete response; median progression-free survival (exploratory end point) was 19.5 and 15.1 months, respectively. In nccRCC (n = 32), ORR was 31% (80% CI, 20 to 44), all partial responses; median progression-free survival was 9.5 months. Grade 3 or 4 treatment-related adverse events (TRAEs) were reported by 71% of patients in the 40-mg ccRCC group, 67% in the 60-mg ccRCC group, and 38% in the nccRCC group; TRAEs leading to discontinuation of both agents occurred in 15%, 6%, and 3% of patients, respectively. There were no grade 5 TRAEs. CONCLUSION The novel combination of cabozantinib plus atezolizumab demonstrated encouraging clinical activity and acceptable tolerability in patients with advanced ccRCC and nccRCC. Disease control was observed across dose levels and histologic subtypes.
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL
Wieduwilt, Matthew J. , Yin, Jun , Wetzler, Meir , Uy, Geoffrey L. , Powell, Bayard L., Kolitz, Jonathan E. , Liedtke, Michaela , Mattison, Ryan J. , Storrick, Elizabeth, Christner, Susan M., Stone, Richard M. , Beumer, Jan Hendrik , Larson, Richard A , Uy, Geoffrey , Stock, Wendy , Lewis, Lionel D. , Devine, Steven M. , Larson, Richard A.

Mayo Clinic

Blood Advances | September 7, 2021 | Volume: 5 | Issue: 22 | Pages: 4691-4700

10.1182/bloodadvances.2021004813 | PMID 34492682 Get It

Abstract Post-remission strategies after dasatinib-corticosteroid induction in adult Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) are not well studied. We evaluated dasatinib and dexamethasone induction then protocol-defined post-remission therapies, including hematopoietic cell transplantation (HCT). Adults (N = 65) with Ph-positive ALL received dasatinib-dexamethasone induction, methotrexate-based central nervous system (CNS) prophylaxis, reduced-intensity conditioning (RIC) allogeneic HCT, autologous HCT, or chemotherapy alone, and dasatinib-based maintenance. Key end points were disease-free survival (DFS) and overall survival (OS). The median age was 60 years (range, 22-87 years). The complete remission rate was 98.5%. With a median follow-up of 59 months, 5-year DFS and OS were 37% (median, 30 months) and 48% (median, 56 months), respectively. For patients receiving RIC allogeneic HCT, autologous HCT, or chemotherapy, 5-year DFS were 49%, 29%, and 34%, and 5-year OS were 62%, 57%, and 46%, respectively. Complete molecular response rate after CNS prophylaxis was 40%. Relative to the p190 isoform, p210 had shorter DFS (median 10 vs 34 months, P = .002) and OS (median 16 months vs not reached, P = .05). Relapse occurred in 25% of allogeneic HCT, 57% of autologous HCT, and 36% of chemotherapy patients. T315I mutation was detected in 6 of 8 marrow relapses. Dasatinib CNS concentrations were low. Dasatinib-dexamethasone followed by RIC allogeneic HCT, autologous HCT, or chemotherapy was feasible and efficacious, especially with RIC allogeneic HCT. Future studies should address the major causes of failure: T315I mutation, the p210 BCR-ABL1 isoform, and CNS relapse. This study was registered at www.clinicaltrials.gov as #NCT01256398.
Assessing Change in Communication Limitations in Primary Progressive Apraxia of Speech and Aphasia: A 1-Year Follow-Up Study
Utianski, Rene L. , Martin, Peter R. , Botha, Hugo , Clark, Heather M. , Josephs, Keith A. , Botha, Hugo , Clark, Heather M , Josephs, Keith A , Utianski, Rene L , Duffy, Joseph R.

Mayo Clinic

American Journal of Speech-Language Pathology | September 7, 2021 | Volume: 30 | Issue: 6 | Pages: 2368-2378

10.1044/2021_ajslp-20-00402 | PMID 34491800 Get It

Purpose Individuals with primary progressive apraxia of speech have apraxia of speech (AOS) as the initial and predominant symptom. Many develop aphasia and/or dysarthria later in the disease course. It was previously demonstrated that patients with neurodegenerative AOS experience reduced participation in communication that is further exacerbated by co-occurring language deficits ( Utianski et al., 2020 ). Measures of disease severity did not necessarily correlate with measures of participation restrictions. The aim of this follow-up study was to describe changes in communication limitations in these patients, again measured by (a) the patient via the Communicative Participation Item Bank (CPIB) and (b) the speech-language pathologist via the American Speech-Language-Hearing Association's (ASHA's) Functional Communication Measures (FCMs) and an adapted motor speech disorder (MSD) severity rating to determine if there are significant changes in these and other objective speech and language measures at follow-up after 1 year. Method Of the 24 patients reported in the study of Utianski et al. (2020) , 17 (10 men, seven women) returned for a second visit approximately 1 year following the first visit. Identical procedures were utilized; the communication measures collected at each visit were statistically compared. Correlations were calculated between the participation ratings and other clinical assessment measures at the second visit and for the change in scores on those measures between the first and second visits. Results There were statistically significant differences in AOS and aphasia severity between visits. There were significant changes in clinical assessments, MSD severity rating, and all ASHA FCMs between visits, but not the CPIB. Correlation analyses suggest the relationships among clinical and participation measures are complex; overall, patients with more severe changes in AOS experienced greater changes in participation restrictions. Conclusions The findings of this study support the use of patient-reported outcome measures as they may better reflect the patient experience, including the influence of factors such as ongoing speech therapy and the emergence of neuropsychiatric features, and associated changes in day-to-day functioning, when other measures may simply index the progression of the disease. Supplemental Material https://doi.org/10.23641/asha.16528512
Quantitative image features from radiomic biopsy differentiate oncocytoma from chromophobe renal cell carcinoma
Jaggi, Arjun , Mastrodicasa, Domenico , Charville, Gregory W. , Jeffrey, R. Brooke , Napel, Sandy , Patel, Bhavik N. , Jaggi, Akshay , Patel, Bhavik

Mayo Clinic

Journal of Medical Imaging | September 7, 2021 | Volume: 8 | Issue: 05 | Pages: No page available

10.1117/1.jmi.8.5.054501 | PMID 34514033 Get It

Reducing Breast Cancer Incidence and Mortality: Rethinking an Approach to Risk Assessment and Prevention
Pruthi, Sandhya , Mussallem, Dawn M., Cornell, Lauren , Klassen, Christine L., Kling, Juliana M. , Cornell, Lauren F , Pruthi, Sandhya , Kling, Juliana M , Mussallem, Dawn M., Klassen, Christine L.

Mayo Clinic

JCO Oncology Practice | September 7, 2021 | Volume: 17 | Issue: 12 | Pages: 717-719

10.1200/op.21.00551 | PMID 34491812 Get It

Predicting incident atrial fibrillation in sinus rhythm: more than just trusting the ‘black box’
Kashou, Anthony H. , Noseworthy, Peter A. , Kashou, Anthony , Noseworthy, Peter A

Mayo Clinic

Heart | September 7, 2021 | Volume: 107 | Issue: 22 | Pages: 1770-1771

10.1136/heartjnl-2021-319385 | PMID 34493548 Get It

Development of gastroenterology and transplant hepatology milestones 2.0: a guide for programs, faculty, and fellows
Shah, Brijen J. , Onken, Jane E., Jou, Janice H. , Obstein, Keith L. , Pardi, Darrell S. , Richter, Seth, Rose, Suzanne , Szyjkowski, Ronald, Fix, Oren K. , Fix, Oren K , Edgar, Laura , Reddy, Gautham

Mayo Clinic

American Journal of Gastroenterology | September 7, 2021 | Volume: 116 | Issue: 10 | Pages: 2009-2013

10.14309/ajg.0000000000001490 | PMID 34491233 Get It

Isotopic Distribution Calibration for Mass Spectrometry
Maus, Anthony , Kemp, Jennifer, Hoffmann, Todd J., Ramsay, Steven L., Grebe, Stefan K., Maus, Anthony D , Kemp, Jennifer V, Grebe, Stefan K G

Mayo Clinic

Analytical Chemistry | September 7, 2021 | Volume: 93 | Issue: 37 | Pages: 12532-12540

10.1021/acs.analchem.1c01672 | PMID 34490782 Get It

Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study
Murakami, Kaoru, Kamat, Ashish M., Dai, Yunfeng, Pagano, Ian, Chen, Runpu, Sun, Yijun, Gupta, Amit, Goodison, Steve, Rosser, Charles J., Furuya, Hideki, Furuya, Hideki , Furuya, Hideki , Murakami, Kaoru, Kamat, Ashish M., Dai, Yunfeng, Pagano, Ian, Chen, Runpu, Sun, Yijun, Gupta, Amit, Goodison, Steve, Rosser, Charles J., Furuya, Hideki

Mayo Clinic

Cancer Biomarkers | September 7, 2021 | Volume: 33 | Issue: 1 | Pages: 151-157

10.3233/cbm-210221 | PMID 34511488 Get It

BACKGROUND: Intravesical Bacillus Calmette-Guerin (BCG), a live attenuated tuberculosis vaccine that acts as a non-specific immune system stimulant, is the most effective adjuvant treatment for patients with intermediate or high-risk non-muscle-invasive bladder cancer (NMIBC). However, to date, there are no reliable tests that are predictive of BCG treatment response. In this study, we evaluated the performance of OncuriaTM, a bladder cancer detection test, to predict response to intravesical BCG. METHODS: OncuriaTM data was evaluated in voided urine samples obtained from a prospectively collected cohort of 64 subjects with intermediate or high risk NMIBC prior to treatment with intravesical BCG. The OncuriaTM test, which measures 10 cancer-associated biomarkers was performed in an independent clinical laboratory. The ability of the test to identify those patients in whom BCG is ineffective against tumor recurrence was tested. Predictive models were derived using supervised learning and cross-validation analyses. Model performance was assessed using ROC curves. RESULTS: Pre-treatment urinary concentrations of MMP9, VEGFA, CA9, SDC1, PAI1, APOE, A1AT, ANG and MMP10 were increased in patients who developed disease recurrence. A combinatorial predictive model of treatment outcome achieved an AUROC 0.89 [95% CI: 0.80–0.99], outperforming any single biomarker, with a test sensitivity of 81.8% and a specificity of 84.9%. Hazard ratio analysis revealed that patients with higher urinary levels of ANG, CA9 and MMP10 had a significantly higher risk of disease recurrence. CONCLUSIONS: Monitoring the urinary levels of a cancer-associated biomarker panel enabled the discrimination of patients who did not respond to intravesical BCG therapy. With further study, the multiplex OncuriaTM test may be applicable for the clinical evaluation of bladder cancer patients considering intravesical BCG treatment.
Rhythm Control in Patients with Heart Failure with Preserved Ejection Fraction: A Meta-Analysis
Chokesuwattanaskul, Ronpichai , Cheungpasitporn, Wisit , Vallabhajosyula, Saraschandra , Jongnarangsin, Krit, Chokesuwattanaskul, Ronpichai , Cheungpasitporn, Wisit , Vallabhajosyula, Saraschandra , Prasitlumkum, Narut , Kewcharoen, Jakrin , Thongprayoon, Charat

Mayo Clinic

Journal of Clinical Medicine | September 7, 2021 | Volume: 10 | Issue: 18 | Pages: 4038

10.3390/jcm10184038 | PMID 34575148 Get It

Background The presence of atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFpEF) dramatically increases higher morbidity and mortality. Recent studies have suggested that early rhythm control may alleviate the burden of poor outcomes. Currently, there remain limited data on whether rhythm or rate control has better efficacy. This study sought to compare both strategies in HFpEF patients with AF. Methods Databases were searched throughout 2020. Studies that reported cardiovascular outcomes amongst HFpEF patients with AF who received either rhythm or rate control were included. Estimates of the effects from the individual studies were extracted and combined using random-effects, a generic inverse variance method of DerSimonian and Laird. Results Five observational studies were included in the analysis, consisting of 16,953 patients, 13.8% of whom were receiving rhythm control. In comparison with rate control, rhythm control was associated with decreased overall mortality rates (pooled RR 0.85, 95% CI 0.75–0.95, with I2 = 0%, p value = 0.009). Conclusions In HFpEF patients with AF, rhythm control was associated with lower mortality, compared to rate control. Further studies are warranted to validate our observation.